Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Net Margin % : -49.51% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Biocytogen Pharmaceuticals (Beijing) Co's Net Income for the six months ended in Dec. 2023 was HK$-211.3 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Dec. 2023 was HK$426.7 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's net margin for the quarter that ended in Dec. 2023 was -49.51%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % or its related term are showing as below:

HKSE:02315' s Net Margin % Range Over the Past 10 Years
Min: -168.84 Med: -133.32 Max: -53.42
Current: -53.42

HKSE:02315's Net Margin % is ranked better than
61.44% of 1027 companies
in the Biotechnology industry
Industry Median: -154.15 vs HKSE:02315: -53.42

Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

-168.84

-153.88

-112.75

-53.42

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial			-132.57	-118.88	-108.14	-58.07	-49.51

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Net Margin %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % falls into.

Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Biocytogen Pharmaceuticals (Beijing) Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-418.864	/	784.143
	=	-53.42 %

Biocytogen Pharmaceuticals (Beijing) Co's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-211.256	/	426.657
	=	-49.51 %

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Biocytogen Pharmaceuticals (Beijing) Co Net Margin % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines